Quantitative MR in multi‐center clinical trials

MRI has a wide variety of applications in the clinical trials process. MR has shown particular utility in the early phases of clinical development, when trial sponsors are interested in demonstrating proof of concept and must make decisions about allocation of resources to a particular compound based on the results from a small number of experimental subjects. This utility is largely due to the many different imaging endpoints that can be measured using MR, ranging from structural (tumor burden, hippocampal volume) to functional (blood flow, vascular permeability) to molecular (hepatic fat fraction, glycosaminoglycan content). The unique flexibility of these systems has proven to be both a blessing and a curse to those attempting to deploy MR in multi‐center clinical trials, however, as differences among scanner manufacturers and models in pulse sequence implementation, hardware capabilities, and even terminology make it increasingly difficult to ensure that results obtained at one center are comparable to those at another. These problems are compounded by the differences between the procedures used in clinical trials and those used in routine clinical practice, which make trial‐specific training for site technologists and radiologists a necessity in many cases. This article will briefly review the benefits of including quantitative MR imaging in clinical trials, then explore in detail the challenges presented by the need to develop and deploy a detailed MR protocol that is both effective and implementable across many different MR systems and software versions. J. Magn. Reson. Imaging 2010; 31: 279–288. © 2010 Wiley‐Liss, Inc.

[1]  C. Zerbini,et al.  Inter- and intrareader variability in the interpretation of two radiographic classification systems for juvenile rheumatoid arthritis , 2003, Pediatric Radiology.

[2]  H. Weinmann,et al.  Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. , 1984, Physiological chemistry and physics and medical NMR.

[3]  N. Thacker,et al.  Breath‐hold perfusion and permeability mapping of hepatic malignancies using magnetic resonance imaging and a first‐pass leakage profile model , 2002, NMR in biomedicine.

[4]  David H. Miller,et al.  A controlled trial of natalizumab for relapsing multiple sclerosis. , 2003, The New England journal of medicine.

[5]  J. Yap,et al.  Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Jingfei Ma Dixon techniques for water and fat imaging , 2008, Journal of magnetic resonance imaging : JMRI.

[7]  Julie Fitzpatrick,et al.  Liver fat content and T2*: simultaneous measurement by using breath-hold multiecho MR imaging at 3.0 T--feasibility. , 2008, Radiology.

[8]  Nick C Fox,et al.  The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.

[9]  Ting-Yim Lee,et al.  Dynamic, contrast-enhanced CT of human brain tumors: quantitative assessment of blood volume, blood flow, and microvascular permeability: report of two cases. , 2002, AJNR. American journal of neuroradiology.

[10]  Huanzhou Yu,et al.  Relaxation times of breast tissue at 1.5T and 3T measured using IDEAL , 2006, Journal of magnetic resonance imaging : JMRI.

[11]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[12]  A. Padhani,et al.  Reproducibility of quantitative dynamic MRI of normal human tissues , 2002, NMR in biomedicine.

[13]  J. Collins Imaging and other biomarkers in early clinical studies: one step at a time or re-engineering drug development? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  E. Ashton,et al.  Conversion From Signal Intensity to Gd Concentration May Be Unnecessary for Perfusion Assessment of Tumors Using DCE-MRI , 2007 .

[15]  R. Cury,et al.  Intra‐ and interreader reproducibility of magnetic resonance imaging for quantifying the lipid‐rich necrotic core is improved with gadolinium contrast enhancement , 2006, Journal of magnetic resonance imaging : JMRI.

[16]  F. Eckstein,et al.  One year change of knee cartilage morphology in the first release of participants from the Osteoarthritis Initiative progression subcohort: association with sex, body mass index, symptoms and radiographic osteoarthritis status , 2008, Annals of the rheumatic diseases.

[17]  Saara Totterman,et al.  Accuracy and reproducibility of manual and semiautomated quantification of MS lesions by MRI , 2003, Journal of magnetic resonance imaging : JMRI.

[18]  E. Ashton Quantitative medical imaging , 2007 .

[19]  Benjamin M Yeh,et al.  Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Van,et al.  Spatial variation of T2 in human articular cartilage. , 1997, Radiology.

[21]  R. Fanin,et al.  Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. , 2002, Arthritis and rheumatism.

[22]  H. Landau Sampling, data transmission, and the Nyquist rate , 1967 .

[23]  N. Patronas,et al.  Serial gadolinium‐enhanced magnetic resonance imaging scans in patients with early, relapsing‐remitting multiple sclerosis: Implications for clinical trials and natural history , 1991, Annals of neurology.

[24]  Kenya Murase,et al.  Efficient method for calculating kinetic parameters using T1‐weighted dynamic contrast‐enhanced magnetic resonance imaging , 2004, Magnetic resonance in medicine.

[25]  F. Cicuttini,et al.  The determinants of change in tibial cartilage volume in osteoarthritic knees. , 2002, Arthritis and rheumatism.

[26]  Jürgen Hennig,et al.  Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. , 2005, European journal of cancer.

[27]  F Eckstein,et al.  In vivo reproducibility of three-dimensional cartilage volume and thickness measurements with MR imaging. , 1998, AJR. American journal of roentgenology.

[28]  H. Potter,et al.  T2 quantitation of articular cartilage at 1.5 T , 2003, Journal of magnetic resonance imaging : JMRI.

[29]  Johanne Martel-Pelletier,et al.  Quantitative magnetic resonance imaging evaluation of knee osteoarthritis progression over two years and correlation with clinical symptoms and radiologic changes. , 2004, Arthritis and rheumatism.

[30]  James N Weinstein,et al.  Reliability of Readings of Magnetic Resonance Imaging Features of Lumbar Spinal Stenosis , 2008, Spine.

[31]  R. Craen,et al.  A CT method to measure hemodynamics in brain tumors: validation and application of cerebral blood flow maps. , 2000, AJNR. American journal of neuroradiology.

[32]  Sharmila Majumdar,et al.  T2 relaxation time measurements in osteoarthritis. , 2004, Magnetic resonance imaging.

[33]  D. Paty,et al.  Interferon beta-1b is effective in relapsing-remitting multiple-sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial , 2011, Neurology.

[34]  Lone Skov,et al.  Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. , 2006, Journal of the American Society of Nephrology : JASN.

[35]  G J M Parker,et al.  Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  D. Louis Collins,et al.  Automated Analysis of Multi Site MRI Phantom Data for the NIHPD Project , 2006, MICCAI.

[37]  Pottumarthi Prasad,et al.  Three-Dimensional T1 Mapping for dGEMRIC at 3.0 T Using the Look Locker Method , 2006, Investigative radiology.

[38]  S. Warach Use of diffusion and perfusion magnetic resonance imaging as a tool in acute stroke clinical trials , 2001, Current controlled trials in cardiovascular medicine.

[39]  P. Tofts Modeling tracer kinetics in dynamic Gd‐DTPA MR imaging , 1997, Journal of magnetic resonance imaging : JMRI.

[40]  J L Evelhoch,et al.  Key factors in the acquisition of contrast kinetic data for oncology , 1999, Journal of magnetic resonance imaging : JMRI.

[41]  E. Ashton Widespread functional and molecular imaging in drug development , 2007, Expert opinion on drug discovery.

[42]  G. Gold,et al.  Iterative decomposition of water and fat with echo asymmetry and least‐squares estimation (IDEAL): Application with fast spin‐echo imaging , 2005, Magnetic resonance in medicine.

[43]  J. Pearlman,et al.  Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study. , 2000, Journal of the American College of Cardiology.

[44]  Claus Christiansen,et al.  The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon? , 2008, Pharmacological research.

[45]  Carl Johan Tiderius,et al.  Delayed gadolinium‐enhanced MRI of cartilage (dGEMRIC) in early knee osteoarthritis , 2003, Magnetic resonance in medicine.

[46]  W. Shi,et al.  Preclinical studies of the novel vascular disrupting agent MN-029. , 2005, Anticancer research.

[47]  J. Lieberman,et al.  Antipsychotic drug effects on brain morphology in first-episode psychosis. , 2005, Archives of general psychiatry.

[48]  R. Herbst,et al.  Angiogenesis and lung cancer: prognostic and therapeutic implications. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  J. Moreland,et al.  Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. , 1971, Arthritis and rheumatism.

[50]  Christian M Langton,et al.  Comparison of fat quantification methods: A phantom study at 3.0T , 2008, Journal of magnetic resonance imaging : JMRI.

[51]  Achim Gass,et al.  Transcranial Low-Frequency Ultrasound-Mediated Thrombolysis in Brain Ischemia: Increased Risk of Hemorrhage With Combined Ultrasound and Tissue Plasminogen Activator Results of a Phase II Clinical Trial , 2005, Stroke.

[52]  W. Kerwin,et al.  Feasibility of in vivo, multicontrast‐weighted MR imaging of carotid atherosclerosis for multicenter studies , 2005, Journal of magnetic resonance imaging : JMRI.

[53]  H. Hussain,et al.  Hepatic fat fraction: MR imaging for quantitative measurement and display--early experience. , 2005, Radiology.

[54]  R. Bakshi,et al.  T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study. , 2002, Archives of neurology.

[55]  D. Burstein,et al.  Nondestructive imaging of human cartilage glycosaminoglycan concentration by MRI , 1999, Magnetic resonance in medicine.

[56]  S. Reeder,et al.  Multiecho water‐fat separation and simultaneous R  2* estimation with multifrequency fat spectrum modeling , 2008, Magnetic resonance in medicine.

[57]  Michael Deimling,et al.  Three-dimensional delayed gadolinium-enhanced MRI of cartilage (dGEMRIC) for in vivo evaluation of reparative cartilage after matrix-associated autologous chondrocyte transplantation at 3.0T: Preliminary results. , 2007, Journal of magnetic resonance imaging : JMRI.

[58]  Steven G Potkin,et al.  A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease , 2005, Nature Medicine.

[59]  Paul Dendale,et al.  Recovery of Regional but Not Global Contractile Function by the Direct Intramyocardial Autologous Bone Marrow Transplantation: Results From a Randomized Controlled Clinical Trial , 2006, Circulation.

[60]  A. Mikos,et al.  Review: tissue engineering for regeneration of articular cartilage. , 2000, Biomaterials.